Pharmafile Logo

News and Press Releases

Acuitas Therapeutics to Showcase LNP Delivery Platform at Four Prestigious Conferences in November 2025

29 October 2025 -- British Columbia, Canada -- Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, today announced its participation in four upcoming conferences in November 2025....

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: November 11, 2025

Acuitas Therapeutics
info@acuitastx.com
6190 Agronomy Road, Suite 205. Vancouver, BC V6T 1Z3

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025

Ocugen
11 Great Valley Parkway Malvern, PA 19355

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...

Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025

Pfizer
235 East 42nd Street NY, NY 10017

CSL Behring and GKV-Spitzenverband Agree on Reimbursement Price for HEMGENIX® – Europe’s First Gene Therapy for Haemophilia B

2 April 2025 -- Marburg, Germany -- CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX. This...

Category: Other, Pharmaceutical
Posted: April 2, 2025

CSL
CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia

Fondazione Telethon Submits US Biological License Application for Etuvetidigene Autotemcel Gene Therapy for the Treatment of Wiskott-Aldrich Sydrome

11 March 2025 -- Milan, Italy -- Fondazione Telethon, an Italian biomedical charity focused on rare genetic diseases, announced that it has submitted the Biologics License Application (BLA) for the...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 11, 2025

Fondazione Telethon
info@telethon.it
Via Poerio 14 - 20129 Milano

Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis

Ingelheim, Germany – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931,...

Category: Biotechnology
Posted: February 24, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark

21 January 2025 – Copenhagen, Denmark – CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX®...

Category:
Posted: January 21, 2025

CSL
CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia

SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products 14 November 2024 – Burlington, MA, USA – SEKISUI Diagnostics’ microbial CDMO business announces...

Category: Manufacturing and Packing
Posted: November 19, 2024

SEKISUI Diagnostics

CSL Behring Announces First Two Patients Treated with HEMGENIX (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Europe

4 July 2024, Marburg, Germany– Global biotechnology leader CSL Behring (ASX: CSL) today announced that two haemophilia B patients were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec) at Haemophilia...

Category: Pharmaceutical
Posted: July 4, 2024

CSL
CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia